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Previous findings have suggested that class IIa histone deacetylases
(HDACs) (HDAC4, -5, -7, and -9) are inactive on acetylated substrates,
thus differing from class I and IIb enzymes. Here,wepresent evidence
supporting this view and demonstrate that class IIa HDACs are very
inefficient enzymes on standard substrates. We identified HDAC
inhibitors unable to bind recombinant human HDAC4while showing
inhibition in a typical HDAC4 enzymatic assay, suggesting that the
observed activity rather reflects the involvement of endogenous
copurified class I HDACs. Moreover, an HDAC4 catalytic domain
purified frombacteriawas 1,000-fold less active than class I HDACs on
standard substrates. A catalytic Tyr is conserved in all HDACs except
for vertebrate class IIa enzymeswhere it is replaced by His. Given the
high structural conservation of HDAC active sites, we predicted the
class IIa His-N2 to be too far away to functionally substitute the class
I Tyr-OH in catalysis. Consistently, a Tyr-to-His mutation in class I
HDACs severely reduced their activity. More importantly, a His-976-
Tyr mutation in HDAC4 produced an enzyme with a catalytic effi-
ciency 1,000-fold higher than WT, and this ‘‘gain of function pheno-
type’’ could be extended to HDAC5 and -7. We also identified
trifluoroacetyl-lysine as a class IIa-specific substrate in vitro. Hence,
vertebrate class IIa HDACs may have evolved to maintain low basal
activities on acetyl-lysines and to efficiently process restricted sets of
specific, still undiscovered natural substrates.
catalytic domain  enzymatic activity  trifluoroacetyl-lysine 
gain of function
Lysine acetylation, the transfer of an acetyl moiety from acetyl-CoA to the -amino group of specific lysine residues, has
recently emerged as a major form of posttranslational modification
regulating functions of core histones and an increasing number of
transcription factors and other cellular and viral proteins (1).
Acetylation, catalyzed by histone acetyl transferases, is a dynamic
process reversed by a class of enzymes known as histone deacety-
lases (HDACs) (2, 3).
Enzymes of theHDAC superfamily can be divided into two large
groups (classes I and II) based on characteristic, conserved se-
quence motifs within a domain of 350 aa harbouring the known
or putative catalytic HDAC domain (3, 4). A subset of class I
members containing HDAC11-related enzymes has recently been
proposed as an independent group (class IV) (5). All three classes
are distinct from the sirtuin-family enzymes (class III) (6) in the
catalytic domain primary sequence and three-dimensional struc-
ture, and in the catalytic mechanism. Several HDAC structures
confirm the presence of a common catalytic site where a Zn ion
coordinated by highly conserved residues contacts the hydroxamate
moiety of HDAC inhibitors (HDACis) (7–10). On this basis, a
common enzymatic mechanism has been proposed focused on the
Zn-catalyzed hydrolysis of the acetyl-lysine amide bond (7).
Metazoan class II HDACs are further divided into subclasses IIa
and IIb. Class IIa members (HDAC4, -5, -7, and -9 in mammals)
form a distinct subgroup because of the presence, in addition to the
HDAC domain, of an extended N-terminal regulatory domain.
Although the role of class IIa HDACs in tissue-specific gene
regulation is well documented (11–14), the contribution of the
HDAC domain to this activity is still controversial. There is ample
evidence that class IIa members exert transcriptional repression
because of their ability to directly inactivate specific transcription
factors. In addition, they can recruit a number of distinct corepres-
sors and/or protein-modifying enzymes that, in turn, inactivate
target transcription factors (4, 15). Most of these protein–protein
interactions occur via theN-terminal domain, whereas the presence
of the catalytic domain is often not strictly required. A natural
HDAC9 splice variant lacking the HDAC domain [myocyte en-
hancer factor-2 interacting transcription repressor/HDAC-related
protein (MITR/HDRP)] as well as analogous artificially truncated
forms of other class IIa members retain full transcriptional repres-
sive functions (16, 17). In addition, several reports have questioned
whether class IIa HDACs possess an intrinsic deacetylase activity,
proposing instead that they function through additional associated
HDACs. All class IIa members expressed in mammalian cells are
known to recruit class I HDACs, which possess high deacetylase
activities both in vitro and in cells (18–20). In particular, HDAC4
and -7 were shown to associate with HDAC3–SMRT/N–CoR
complexes through their HDAC domains (19, 20). Site-directed
mutagenesis of conserved active site residues in HDAC4 failed to
clarify this point in that all HDAC4 mutants showing impaired
deacetylase activity in vitro also lost the ability to interact with
HDAC3–SMRT/N–CoR complexes (20). Consequently, it remains
unclear whether the resulting drop in overall deacetylase activity
was caused by a loss of intrinsic HDAC4 activity or loss of the
associated highly activeHDAC3complex.Attempts to obtain active
recombinant class IIa HDACs in heterologous systems were also
unsuccessful (21).Whether this is due to a lack of putative cofactors
required to boost class IIa HDAC intrinsic activity or a lack of
endogenous class I enzymes is still unknown. An additional limi-
tation is the lack of isotype/class-specific HDACis that may help
distinguishing the contribution of class IIa intrinsic catalytic activity
from that of associated class I HDACs.
We addressed these issues by using HDAC4 as a represen-
tative class IIa model system with four different approaches:
(i) comparison of the inhibitory potential of selected HDACis
on HDAC4-associated deacetylase activity with their capabil-
ity to bind HDAC4 catalytic domain; (ii) functional analysis of
a purified HDAC4 catalytic domain expressed in Escherichia
coli; (iii) structure-guided mutagenesis of a single catalytic
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residue present only in vertebrate class IIa HDACs; and (iv)
screening for HDAC4-specific substrates. Collectively, our
findings, extended also to other class IIa enzymes, led to the
following conclusions. Class IIa HDACs possess a weak but
measurable intrinsic capability of hydrolyzing acetyl-lysines in
vitro. Most of the enzymatic activity associated with class IIa
HDACs ectopically expressed in mammalian cells is due to
endogenous class I HDACs present in class IIa immunocom-
plexes. More importantly, we could completely ascribe the low
catalytic efficiency of mammalian class IIa enzymes to the
presence of a unique H residue replacing the catalytic Y
conserved in all other prokaryotic and eukaryotic deacety-
lases. Indeed, catalytic activity toward canonical HDAC sub-
strates could be restored by a single H-to-Y substitution in the
active site. Finally, we have identified trif luoroacetyl-lysine as
a class IIa-specific substrate in vitro.
Results
Sequence and Structure Analysis Indicates that Vertebrate Class IIa
HDACs Have Distinct Properties.Despite the differences in sequence
motifs distinguishing class I and IIHDACs [supporting information
(SI) Fig. 7], the active site is structurally highly conserved, and all
functional residues are in equivalent positions. A common feature
of all HDAC structures is the presence of a Y residue postulated to
act as a transition-state stabilizer (7). However, examination of
sequence conservation across many HDACs revealed an unex-
pected feature exclusive to vertebrate class IIa HDACs (Fig. 1A).
In the vertebrate class IIa HDACs, the catalytic Y is replaced by an
H, a conservative substitution, whereas other functional residues
are virtually always conserved (SI Fig. 7). In the structures of the
bacterial HDAC homolog HDLP (7), HDAC8 (9, 10), and a class
II bacterial homolog (8), this Y is located close to the end of a
-strand, a structural element conserved among all these homologs
including the local backbone conformation (data not shown). To act
as transition-state stabilizer, the Y side chain has to be oriented
along the -strand, as seen in all these crystal structures. For
vertebrate class IIa HDACs, the Y is replaced by an H side chain,
which is too short to reach into the active site (Fig. 1B). In class IIa
HDACs, three different residues (Y, H, and F) are observed at this
position and, given the particular structural context, it is unlikely
that for each residue a concomitant conformational change would
occur.
Consequently, we hypothesized that the catalytic domain of
vertebrate class IIa HDACs should be less effective in processing
canonical HDAC substrates containing acetyl-lysines. Neverthe-
less, the high conservation of active-site and substrate-binding
residues (SI Fig. 7) suggests that class IIa HDACs should be
functional enzymes.
Class I HDACs with the Y Mutated into H Are Inactive on Canonical
HDAC Substrates. One implication of our hypothesis was that class
I enzymatic activities should be affected by substituting the catalytic
Y with an H. We therefore mutated Y-298 into H in the active site
of HDAC3, a representative class I member. WT and mutant
flag-tagged HDAC3 enzymes were coexpressed in HeLa cells and
coimmunopurified together with a GAL4 DBD fusion of the
N-CoR Deacetylase Activation Domain (N-CoR DAD) (22, 23).
As predicted, replacing the active site Y with H was sufficient to
abolish the enzymatic activity on a histone H4-derived peptide
containing a single acetyl-lysine (pepH4-AcK16) (Fig. 2A). Iden-
tical results were obtained on 3[H]-acetylated core histones (data
not shown). Mutations of HDAC active-site residues are reported
to impair interactions with protein-binding partners, suggesting that
they may also cause alterations in the overall catalytic domain
structure (24).However, theY298H substitution inHDAC3did not
affect its association with N-CoR DAD (Fig. 2B), suggesting that
the integrity of the catalytic domain was preserved. Furthermore,
replacement of Y with H produced a loss-of-function phenotype as
severe as that caused by replacement with F (SI Fig. 8A). Although
similar in size and shape, F lacks the functional hydroxyl group
present in Y and therefore cannot contribute to catalysis as a
transition-state stabilizer. This mutant also preserved the ability to
bind N-CoR DAD (SI Fig. 8B), thus confirming that the substitu-
tion with F is conservative regarding the active site geometry.
Finally, we demonstrated a more general role for the catalytic Y by
mutating Y-303 into H in the active site of HDAC1-FLAG. As
shown in SI Fig. 8C, the mutation actually reduced HDAC1
deacetylase activity 5- to 8-fold. Notably, key interactions with
different endogenousHDAC1/2 binding proteins andwithHDAC2
were not affected by themutation (SI Fig. 8D). Indeed, the residual
activity shown by themutant can probably be ascribed to associated
native HDAC2.
Class IIa HDACs with the H Mutated into F Are Not Impaired in Their
Catalytic Activity on Canonical HDAC Substrates. Having demon-
strated that Y mutants of class I HDACs lose most of their
canonical catalytic activity, we used a similar approach to study the
intrinsic enzymatic activity of HDAC4. Ectopically expressed class
IIa enzymes are generally found to be associated with highly active
Fig. 1. Sequence motif conservation and active-site geometry. (A) Class-
specific sequence motif completely conserved in class I. Conservation is gen-
erally high also within class II, with the notable exception of class IIa. (B)
Active-site region of a bacterial class II homolog. To substitute Y as transition-
state stabilizer, the H has to move closer to the active site. The LEGGYmotif is
indicated, as is the interactionbetween theYanda representativehydroxamic
acid moiety (INH).
Fig. 2. The HDAC3 Y(298)H substitution generates a loss-of-function mutant.
(A) Enzymatic activities of WT and Y(298)H-mutated HDAC3-FLAG (HDAC3-F)
proteins on pepH4-AcK16. (B) Western blot of HDAC3-FLAG immunocomplexes
assayed inA by using anti-FLAG (HDAC3-F) or anti-Gal4 (GAL4-DAD) antibodies.
Ten, 20, and 40 nMWT and mutant HDAC3 were analyzed.
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endogenous class I enzymes such asHDAC1, -2, and -3 (refs. 18–20
and data not shown).Measuring the deacetylase activity ofHDAC4
complexes purified from mammalian cells would therefore only
reflect the overall activity of the complex and not necessarily that
of HDAC4. On the other hand, if HDAC4 contributes significantly
to this activity, a mutation of H into F, analogous to class I mutants,
should have a strong impact on the overall deacetylase activity.
C-terminally flag-tagged HDAC4 proteins, either WT or H976F,
were purified fromHEK293 cells. As shown in SI Fig. 8E, mutation
into F did not alter the activity of the purified HDAC4 complex on
pepH4-AcK16. Interestingly, the F mutant preserved WT interac-
tions with the endogenous HDAC3–N–CoR complex (SI Fig. 8F)
that, according to published data, should be mainly responsible for
the activity on acetylated substrates (20).
Inhibition by Selected HDACis of HDAC4-Associated Activity Does Not
Correlate with Their Binding to the HDAC4 Catalytic Domain. Inde-
pendent evidence confirmed that HDAC4-FLAG does not signif-
icantly contribute to the observed enzymatic activity, which rather
reflects the involvement of endogenous copurified class I HDACs.
Two structurally dissimilarHDACis, the hydroxamateLAQ824 and
the cyclic tetrapeptide apicidin, were selected as test molecules for
binding studies. Both compounds showed similar nanomolar po-
tencies in inhibiting the deacetylase activity of ectopically expressed
HDAC3-FLAG and HDAC4-FLAG (Fig. 3A). Therefore, they
were modified to include a photoactivatable cross-linker and the
trapping molecule biotin (Fig. 3A). An identical modified molecule
lacking theHDACimoiety was included as negative control. Direct
binding to HDAC4-FLAG was measured in two ways: (i) in
pull-down experiments by capturing HDAC4-FLAG from a cell
extract on streptavidin-coated beads preadsorbed with the biotin-
ylated derivatives (Fig. 3B); and (ii) by UV cross-linking and
analysis of the protein covalently bound to the biotinylated com-
pounds in ExtrAvidin-Western blots (Fig. 3C). Although LAQ824
and apicidin, as well as their derivatives, were equipotent in
inhibiting HDAC4-FLAG-associated activity (Fig. 3A), of the two,
only the LAQ824 derivative significantly and specifically bound
HDAC4-FLAG (Fig. 3 B and C). UV cross-linking experiments
withHDAC3-FLAGandHDAC6-FLAG showed instead a perfect
correspondence between sensitivity and binding to both com-
pounds (SI Fig. 9A). These findings were confirmed and extended
by competition experiments in which binding to the LAQ824-based
compound was challenged by adding different HDACis at suitable
molar excesses (SI Fig. 9B andC). Table 1 summarizes comparative
data of the binding and inhibition properties of selected compounds
on HDAC4-FLAG. The lack of correlation between binding and
Fig. 3. HDAC4 compounds binding assays. (A) IC50 values of LAQ824 and apicidin on HDAC4-FLAG and HDAC3-FLAG activities and structures of the
corresponding linkerized/biotinylated derivatives. A negative control lacking the HDACi moiety is also shown. The IC50 values of the modified compounds for
HDAC4-FLAG (HDAC4-F) are reported. (B) HDAC4-FLAG pull-down on streptavidin-coated magnetic beads preabsorbed with each of the three biotinylated
compounds shown in A. A representative Coomassie blue-stained SDS/PAGE gel loaded with the unbound (U) and bound (B) fractions is shown. (C) UV
cross-linking of HDAC4-FLAG to each of the three compounds described inA. A representative ExtrAvidinWestern blot is shown. A control lane developed with
anti-FLAG antibodies after a mock UV treatment is also shown.
Table 1. Binding and inhibitory activities of selected HDACi on different HDAC4 variants
Compound
Binding assay
HDAC4-F  CD
Histone assay
HDAC4-F*
Biomol assay
HDAC4-F*
Biomol assay
mHDAC4-F†
Biomol assay
mHDAC4-CD†
MS-275  510 (62) 3,017 (422) NA up to
10,000
NA up to
10,000
Apicidin  2.4 (0.5) 1.2 (0.3) NA up to
10,000
NA up to
10,000
Open Apicidin  152 (24) 88 (11) NA up to
10,000
NA up to
10,000
LAQ824  4 (1.3) 1 (0.5) 3 (0.8) 2.5 (0.7)
IC50 values (nM) are the means of at least two independent experiments. NA, not active.
*[HDAC4-F] was 15 nM; in these assays endogenous class I HDAC activity is measured.
†[mHDAC4] was 1 nM.
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inhibition observed with apicidins and MS-275 confirmed that
HDAC4 does not contribute to the deacetylase activity of the
HDAC4 complex (or does so only to a marginal extent).
HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Sub-
strates in the Absence of Associated Endogenous Class I HDACs. A
third and even stronger evidence forWTHDAC4 lacking canonical
deacetylase activity came fromexperiments on the isolated catalytic
domain. Based on HDAC sequence homologies, an N-terminally
truncated HDAC4 catalytic domain (HDAC4-CD) starting at Thr
653 was cloned, expressed in E. coli, and purified to homogeneity.
This protein was efficiently pulled- down on biotinylated LAQ824
beads (Fig. 4A), suggesting that the structural integrity of the
catalytic domain was preserved in the recombinant truncated
mutant. Pull-down was significantly reduced by preincubation with
an excess of free LAQ824, whereas apicidin and MS275 did not
show competition, thus confirming and directly validating the
results obtained with ectopic HDAC4-FLAG. When challenged in
activity assays, HDAC4-CD showed a measurable deacetylase
activity both in the histone-based (Fig. 4B) and the commercial (SI
Fig. 10A) HDAC assays. However, this activity was at least 1,000-
fold lower than that of class I HDACs ectopically expressed in
mammalian cells (SI Fig. 10B) and 100-fold lower than that
associated with the HDAC4-FLAG complex purified from mam-
malian cells (data not shown). In addition, HDAC4-CD was
completely inactive on pepH4-AcK16 and on a number of acety-
lated peptides grafted fromnonhistonicHDACsubstrates (data not
shown). Interestingly, apicidin, a potent inhibitor of the HDAC4-
FLAG complex activity (Fig. 3A), was instead unable to affect the
enzymatic activity of the isolated domain (Fig. 4B and SI Fig. 10A),
consistent with the observed lack of binding.
Together, these results demonstrate that HDAC4 intrinsic cat-
alytic activity is low on canonical acetylated substrates and does not
contribute significantly to the overall activity observed in purified
ectopic HDAC4 complexes.
An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
According to the structural predictions, the only feature missing
in the catalytic domain of HDAC4 for being a bona fide HDAC
is the Y residue involved in stabilizing the transition-state
intermediate. Consequently, the substitution of H-976 with Y in
HDAC4 was expected to represent a ‘‘gain-of-function’’ muta-
tion. H976Y mutants were therefore generated and expressed as
HDAC4-FLAG in mammalian cells and HDAC4-CD in E. coli
and tested for histone deacetylase activity. As predicted, both
mutated enzymes now showed high deacetylase activity, in-
creased 20-fold for HDAC4-FLAG and 1,000-fold for
HDAC4-CD in the linear range of the reaction (Fig. 5 A and B,
respectively), reaching levels comparable to class I enzymes. This
experimental evidence also proved the HDAC4 catalytic domain
to be properly folded under our experimental conditions, be-
cause a single amino acid substitution was sufficient to confer
high enzymatic activity. Y-substituted HDAC4 proteins main-
tained their gain-of-function phenotype also on the Fluor de Lys
substrate, allowing comparative measurements of inhibition
constants for a panel of well known HDACis (Table 1, mH-
DAC4). Different than WT HDAC4-FLAG, Y mutants were
sensitive only to the inhibitory effect of LAQ824, but they were
highly resistant to inhibition by compounds belonging to differ-
ent chemical classes (MS-275, apicidin, and its open derivative),
all of which are active on class I HDACs (data not shown).
Remarkably, compounds that did not inhibit the H976Y-
substituted enzymes were those that did not bind WT HDAC4,
thus implying that the mutant proteins retain the WT selectivity
of interactions. Furthermore, the HDAC4-CD mutant showed
an inhibition profile identical to that of the full-length HDAC4-
FLAGmutant, suggesting that the observed selectivity is directly
related to the catalytic domain and does not depend on addi-
tional N-terminal regions.
To assess whether this gain-of-function effect is a general prop-
erty of class IIa enzymes, we performed equivalent experiments on
HDAC5 H1006Y and HDAC7 H843Y purified from mammalian
cells (SI Fig. 11 A and B, respectively). Again Y mutants exhibited
strongly increased activity compared with WT and, like the
HDAC4 mutant, could be inhibited by LAQ824 but were resistant
to apicidin.
HDAC4-Mediated Transcriptional Repression Does Not Depend on Its
Catalytic Activity. It is well documented that class IIa HDACs are
potent and selective transcriptional repressors (4). Having ascer-
tained that HDAC4 is not a proficient deacetylase on canonical
substrates in vitro, we asked to what extent its enzymatic activity is
responsible for the transcriptional repression exerted in HeLa cells
expressing a MEF2-dependent reporter gene (SI Fig. 12). The
H976Y mutation did not enhance HDAC4 transcriptional inhibi-
tory activity, despite its clear effect on the enzymatic activity in vitro
Fig. 4. Functional characterization of the isolated HDAC4-CD purified from
E. coli. (A) Pull-down of HDAC4-CD on biotinylated LAQ824-coated beads
after preincubation with the indicated HDACis [LAQ824 (Laq), apicidin (Api),
orMS275 (MS)]. In laneC, control beads coatedwith the compound lacking the
HDACi moiety were used. A representative Coomassie blue-stained SDS/PAGE
gel is shown. (B) Enzymatic activity of HDAC4-CD on acetylated histones. One
micromolar protein was needed to measure significant activity levels.
Deacetylation was assayed in the absence or presence of 10 M apicidin
(inactive) or LAQ824 (active).
Fig. 5. TheHDAC4H976Y substitution generates a gain-of-functionmutant.
(A) Comparison of the enzymatic activities exhibited by WT, H976F-mutated,
and H976Y-mutated HDAC4-FLAG proteins immunopurified from mamma-
lian cells. (B) Comparison of the enzymatic activities of WT and H976Y-
mutated HDAC4-CD proteins purified from E. coli. Data obtained on acety-
lated histones are shown.
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(SI Fig. 12A). In addition, treatment with HDACis partially re-
lieved the observed repression, implying the involvement of an
active deacetylase (SI Fig. 12B). However, LAQ824 and apicidin
had similar effects in this assay in contrast to the different inhibitory
potencies and binding affinities shown in vitro. These findings
support consolidated evidence that the catalytic activity of HDAC4
is dispensable for transcriptional repression and suggest instead a
role for one or more class I enzymes present in the HDAC4
multiprotein complex.
Identification of a Class IIa-Specific Substrate. Having ascertained
that class IIa HDACs are not proficient enzymes on acetyl-lysines,
we sought alternative in vitro substrates. By screening a panel of20
acylated lysine-like molecules, we identified only one substrate, a
trifluoroacetyl-lysine, on which both full-length and the catalytic
domain of HDAC4 were highly active (Fig. 6 and data not shown).
Moreover, this compound was actively and specifically processed by
three different class IIa enzymes, whereas it was a poor substrate for
both class I and class IIb HDACs (Fig. 6).
Discussion
The conservation of active-site residues and the concomitant
preservation of structural features in the active site is a hallmark of
many enzymes. Initially, HDACs seem to follow this trend because
crystal structures of their catalytic domains confirm a highly
conserved active site and substrate-binding pocket. The conserva-
tion extends across classes I, II, and IVdespite the presence of some
class-specific sequence motifs and the generally low homology
between classes. In the HDAC active site, a central motif of
completely conserved residues coordinates a Zn ion and is com-
plemented by a second group of highly conserved residues involved
in the enzymatic reaction and substrate binding. One of these
residues, a Y, had been postulated to act as a transition-state
stabilizer because of its position in various enzyme-inhibitor com-
plexes. Although generally highly conserved, this residue is substi-
tuted by H in all vertebrate class IIa HDACs. Examination of the
available structures showed thatH, a conservative substitution ofY,
should not be able to act as a transition-state stabilizer, thus
compromising enzymatic activity according to the proposed mech-
anism. The picture that emerged from this analysis for HDAC4
(and other vertebrate class IIa enzymes) is that of a theoretically
fully functional enzyme if not for the lack of this single important
detail.
This prediction was substantiated experimentally in class I en-
zymes that lost enzymatic activity when mutating Y into H (or F).
Further, our hypothesis also predicted that, by changing the H into
Y in vertebrate class IIa enzymes, a completely functional active site
should be generated. Indeed, in contrast to their WT counterparts,
class IIa HDAC Y mutants became fully proficient enzymes with
respect to their Lys deacetylase activity on canonical substrates.
This finding was confirmed both in the isolated catalytic domain
expressed in a prokaryotic system as well as for the full-length
enzymes expressed in mammalian cells, including HDAC5 and -7.
We have identified a class IIa-specific synthetic substrate,
trifluoroacetyl-lysine.Mechanistically, the presence of the trifluoro
group should destabilize the amide bond and thus favor the reaction
even in the absence of transition-state stabilization, as postulated
for the His-containing class IIa HDACs. Accordingly, potential
class IIa-specific natural substrates mimicking the trifluoroacetyl-
lysine might contain a hydrolyzable bond intrinsically less stable
than an amide bond.
In addition to their known function as transcriptional repressors
acting in cohort with associated class I enzymes and directed toward
Lys deacetylation, our results point to a previously unknown,
specific catalytic activity of vertebrate class IIa HDACs. Specificity
is apparently dictated by a single amino acid change in an otherwise
conserved active site. Sequence analysis further suggests this ‘‘H-
associated’’ specificity is restricted to vertebrates. Invertebrates like
Caenorhabditis elegans and Drosophila melanogaster conserve the
canonical Y and, accordingly, should retain canonical HDAC
catalytic activity as suggested previously (25, 26). The emergent
theme predicts class IIaHDACswith intrinsically different catalytic
activities for the two groups: (i) canonical HDAC activity in
invertebrates and (ii) a more specialized enzymatic activity in
vertebrates. Yet another residue, F, is instead found in class IIa
homologs of the ascidians Ciona intestinalis, Ciona savignyi, and
Halocynthia roretzi. Based on our results, the presence of an F
should be incompatible with activity, provided that the catalytic
mechanism is conserved. Interestingly, ascidian class IIa sequences
also lack one of the conserved Zn ligands, a D is replaced by an S
(SI Fig. 7). The evolutionary conservation of this apparently
defective active-site configuration is rather unexpected as are its
functional implications.
The identification of additional biological activities/substrates
that depend on class IIa H-associated activity in mammalian cells
requires further work. Ectopically expressed HDAC4 and -5 have
been shown to deacetylate Runx3 (27). However, those experi-
ments did not allow discrimination of class IIa HDAC intrinsic
deacetylase activities from those of associated class I endogenous
enzymes. During the screening of a library of acetylated peptides
representative of the known ‘‘acetylome,’’ we have indeed observed
(P.G., A.L., C.P., andC.S., unpublished data) thatHDAC3, and not
HDAC4, -5, -7, or the HDAC3 Y298F mutant, is able to efficiently
deacetylate two of the three Runx3 K residues (K148 and K186)
previously shown to be acetylated (27). More recently, it has been
shown that both Sirt1 (28) and HDAC3 (29), and not HDAC4 or
-5, efficiently deacetylate MEF2D, thus contributing to MEF2D-
dependent transcriptional repression. Our MEF2 reporter gene
data are in agreement with these findings, excluding HDAC4
catalytic activity for being responsible for transcriptional repression
and pointing to the involvement of class I enzymes that are equally
sensitive to the inhibition by both LAQ824 and apicidin.
Besides their transcriptional corepressor functions, a number of
‘‘atypical’’ biological activities have been described for different
class IIa members. It has been reported that HDAC7 localizes to
mitochondria and may regulate the initiation of apoptosis (30).
HDAC7 was also shown to bind HIF-1 and activate transcription
(31). More recently, HDAC4, together with HDAC6, was also
found to interact with and stabilizeHIF-1 (32). A role forHDAC4
in the DNA damage-response pathway was proposed based on
colocalization with 53BP1 nuclear foci after exposure to agents
Fig. 6. Trifluoroacetyl-lysine is a class IIa-specific substrate in vitro. (A) The
fluorogenic derivative of the trifluoroacetyl-lysine compound is shown. (B)
The catalytic activities of flag-tagged HDACs representative of class I, IIa, and
IIb were measured on the trifluoroacetyl-lysine substrate shown in A.
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causing double-stranded DNA breaks (33). Furthermore, indepen-
dent findings showed that the hydroxamate LBH589 confines
HDAC4 to the cytoplasm and increases the duration of -H2AX
foci in irradiated cells (34). However, the precise role of HDAC4
catalytic activity in these biological contexts remains to be
elucidated.
Finally, our data also imply that class IIa HDACs should be
considered a distinct class of therapeutic targets, concerning both
their natural substrates and selective mechanisms of inhibition.
Future work will undoubtedly identify these yet unknown physio-
logical substrates and further reveal the already complex biological
activities of these enzymes.
Methods
Sequence Analysis and Modeling. Class IIa HDAC sequences for C.
intestinalis, C. savignyi, and H. roretzi were assembled by using data
from the National Center for Biotechnology Information nucleo-
tide sequence database (see legend to SI Fig. 7). Sequences were
aligned with CLUSTALW followed by manual refinement with
Genedoc (www.psc.edu/biomed/genedoc). Graphical display and
structural analysis of the bacterial class II homolog (Protein Data
Bank entry 1ZZ1, www.pdb.org) was performed by using Viewer-
Lite (Accelrys, San Diego).
Deacetylase Assays. The histone and peptide activity assays were
performed by using 3[H]acetyl-core histones purified from HeLa
cells as described in refs. 35 and 36 or a fluorescent histone H4
(AcK16) peptide substrate [pepH4-AcK16: Mca-GAK(-
Ac)RHRKV-NH2; AnaSpec, San Jose, CA]. Enzymes were incu-
bated in 100 l of assay buffer (50 mM Hepes, pH 7.4/5%
Glycerol/0.01% Triton X-100/0.1 mg/ml BSA) containing 5–8 g
(7,000–10,000 dpm) of 3[H]acetyl-histones or 4 MpepH4-AcK16.
Reactions were performed at room temperature (RT) for 4 h and
terminated with 20 l of a 0.5 M HCl/1 M acetic acid mixture
(histones), or 10% TFA (peptide). 3[H]acetic acid released from
histones was extracted with 1 ml ethyl acetate, 900 l of solvent
phase containing free 3[H]acetic acid and 90 l of aqueous phase
containing unprocessed 3[H]acetyl-histones were collected, and
radioactivity was measured by scintillation counting. The percent-
age conversion was calculated as: [(dpm product/dpm product 
dpm substrate) 100]. The percentage of pepH4-AcK16 converted
to the corresponding deacetylated product was determined by
HPLC on a Beckman C18 column (Beckman Instruments, Colum-
bia, MD) eluted with a linear gradient of acetonitrile in H2O. The
HDAC fluorescent activity assay (BIOMOL Research Laborato-
ries, Plymouth Meeting, PA) was performed in 96-well plates
according to the manufacturer’s instructions by using either the
commercial Fluor de Lys substrate (KI-104) or the trifluoroacetyl-
lysine substrate (for synthesis, see SI Methods).
HDACi activities were evaluated by preincubating compounds
and recombinant enzymes in assay buffer at RT for 15 min, before
substrate addition. Mean values of at least two independent assays
are reported.
HDAC4 Compound Binding Assays. For cross-linking experiments, 10
nM affinity-purified flag-tagged HDAC4, HDAC3, or HDAC6
were incubated under activity assay conditions with the LAQ824
derivative, the apicidin derivative, or the negative-control com-
pound lacking the HDACi moiety. Compounds were tested at 40,
60, or 90 nM concentrations, corresponding to 1:4, 1:6, or 1:9
protein:compound ratios. After 2 h of incubation at RT, UV
cross-linking was performed, and polypeptides covalently cross-
linked to the biotinylated compounds were separated by SDS/
PAGE and analyzed by Western blot using alkaline phosphatase-
conjugated ExtrAvidin (Sigma, St. Louis, MO).
For pull-down experiments with HDAC4-FLAG, soluble ex-
tracts from HEK293 cells transiently transfected with pHDAC4-
FLAG were prepared. Suitable aliquots containing 2.5 g of
HDAC4-FLAG (0.2 M in 100 l) were incubated for 3 h at RT
with streptavidin-coated magnetic beads (Dynal Biotech, Lake
Success, NY) pretreated with each of the three 5 M biotinylated
compounds also used in cross-linking experiments. Unbound pro-
teins were collected, and bound proteins were detached from the
compound-coated beads by boiling in SDS dye. Both fractions were
loaded on SDS/PAGE gels and visualized by Coomassie blue
staining. For competition experiments, different HDACis were
added at concentrations of 50 M to the HDAC4-FLAG-
overexpressing extracts for 3 h at RT before incubation with the
LAQ824-matrix. Similar conditions were used for pull-down ex-
periments by using the recombinant HDAC4-CD purified from
E. coli.
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